(1R,3R)-5-Methyl-cyclohexane-1,2,3,5-tetraol | 98429-49-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (1R,3R)-5-Methyl-cyclohexane-1,2,3,5-tetraol
• CAS: 98429-49-3
• 化学式: C₇H₁₄O₄
• 分子量: 162.186
• InChiKey: NSFRBXVOBLRKOW-GBNDHIKLSA-N

反应信息

• 作为产物：
  描述：

  乙酸酐 、 Toluene-4-sulfonic acid (3aR,4R,6S,7aR)-6-hydroxy-2,2,6-trimethyl-hexahydro-benzo[1,3]dioxol-4-yl ester 生成 (1R,3R)-5-Methyl-cyclohexane-1,2,3,5-tetraol
  参考文献：
  名称：

  甲羟戊内酯的绝对构型

  摘要：

  甲羟戊酸内酯的天然对映异构体通过其对映体与奎尼酸的直接相关性显示具有（R） -（-）-构型XVIII。

  DOI：

  10.1002/hlca.19600430608

文献信息

• [EN] TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS THERE OF<br/>[FR] INHIBITEURS DE TYROSINE KINASE, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
  申请人：BETTA PHARMACEUTICALS CO LTD

  公开号：WO2020114499A1

  公开（公告）日：2020-06-11

  The present invention relates to compounds of Formula (I), methods of using the compounds as Trk inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections. (I)

  本发明涉及式(I)的化合物，使用这些化合物作为Trk抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或改善癌症或感染等疾病或疾病方面是有用的。 (I)
• 19-Nor-Vitamin D Analogs with 1,2-Dihydrofuran Ring
  申请人：DeLuca Hector F.

  公开号：US20100009944A1

  公开（公告）日：2010-01-14

  19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 1α-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of cancers, secondary hyperparathyroidism, psoriasis, or other skin diseases.

  描述了具有额外二氢呋喃环连接类似物A环的1α-氧和碳-2的19-去维生素D类似物，以及其药用。这些化合物在体外和体内表现出选择性活性，使它们成为治疗自身免疫疾病、某些类型的癌症、继发性甲状旁腺功能亢进症、银屑病或其他皮肤疾病的治疗药物。
• BRANCHED POLYALKYLENE GLYCOLS
  申请人：Yamasaki Motoo

  公开号：US20080125350A1

  公开（公告）日：2008-05-29

  The present invention provides a branched polyalkylene glycol wherein three or more single-chain polyalkylene glycols and a group having reactivity with an amino acid side chain, the N-terminal amino group or the C-terminal carboxyl group in a polypeptide or a group convertible into the group having reactivity are bound; and a physiologically active polypeptide modified with the branched polyalkylene glycol.

  本发明提供了一种分支状聚烷基乙二醇，其中三个或更多单链聚烷基乙二醇和一个具有与多肽中氨基酸侧链、N-末端氨基基团或C-末端羧基基团反应性的基团，或可转化为具有反应性基团的基团，被结合；以及经过分支状聚烷基乙二醇修饰的生理活性多肽。
• Quinic acid-modified nanoparticles and uses thereof
  申请人：Purdue Research Foundation

  公开号：US11154514B2

  公开（公告）日：2021-10-26

  The present invention generally relates to targeted nanoparticle delivery to E-selectin- or P-selectin-positive cells or tissues. In particular, this invention discloses a method for preparing quinic acid-modified nanoparticles for targeted drug delivery to cancerous cells or tissues via E-selectin- or P-selectin-mediated transcytosis. The invention described herein also pertains to pharmaceutical compositions and methods for treating cancers.

  本发明一般涉及向 E-选择素或 P-选择素阳性细胞或组织靶向递送纳米颗粒。特别是，本发明公开了一种制备奎宁酸修饰纳米粒子的方法，用于通过 E-选择素或 P-选择素介导的转囊作用向癌细胞或组织靶向递送药物。本发明还涉及治疗癌症的药物组合物和方法。
• MODULATIONS OF PROTEASE ACTIVATED RECEPTORS
  申请人：Fairlie David Paul

  公开号：US20130184226A1

  公开（公告）日：2013-07-18

  The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.